Samrat Pharmachem Limited Receives Credit Rating Upgrade from Crisil

Samrat Pharmachem Limited has announced a credit rating upgrade from Crisil Limited, marking a positive development for the pharmaceutical chemicals manufacturer and exporter. The company disclosed this information in compliance with regulatory requirements under SEBI listing obligations.

Credit Rating Enhancement Details

Crisil Limited has revised its assessment of Samrat Pharmachem Limited's creditworthiness, upgrading the rating on the company's bank facilities. The rating agency has moved the company's credit profile from a negative outlook to a stable outlook.

Rating Component:	Previous Rating	New Rating
Long-term Rating:	Crisil BB+/Negative	Crisil BB/Stable
Short-term Rating:	Crisil A4+	Crisil A4+

Regulatory Compliance and Disclosure

The announcement was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Company Secretary and Compliance Officer Nishant Kankaria signed the disclosure document, ensuring proper regulatory compliance.

The company has made this information publicly available on its official website at www.samratpharmachem.com , providing transparency to all stakeholders including investors, creditors, and business partners.

Company Background

Samrat Pharmachem Limited operates as a manufacturer and exporter of pharmaceutical chemicals, with its registered office and factory located at GIDC Phase 4, Ankleshwar, Gujarat. The company maintains its corporate office in Andheri West, Mumbai, serving as the operational hub for its business activities.

The credit rating upgrade reflects the rating agency's assessment of the company's financial position and creditworthiness, which could potentially impact the company's borrowing costs and access to credit facilities from banking institutions.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+4.32%	+0.68%	-1.41%	-34.97%	-36.69%	+48.63%

Samrat Pharmachem Limited has announced that its Board of Directors will convene on May 30, 2026, to review and approve the company's audited financial results for the financial year ended March 31, 2026. The pharmaceutical chemicals manufacturer issued the notice on March 25, 2026, in compliance with regulatory requirements.

Board Meeting Details

The board meeting is scheduled to take place at the company's corporate office with specific timing and agenda items outlined for stakeholder information.

Parameter:	Details
Meeting Date:	May 30, 2026
Meeting Time:	2.00 PM
Venue:	Corporate Office, Mumbai
Address:	701/702 Business Square, M.A. Road, Andheri (West), Mumbai - 400058

Meeting Agenda and Compliance

The primary agenda involves consideration and approval of audited standalone financial results prepared under Indian Accounting Standards (Ind-As) for FY26. The board will also review statutory auditor reports accompanying the financial statements. This notice has been issued pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting notice will be made available on the company's website at www.samratpharmachem.com as required under Regulation 46 of SEBI LODR regulations. Company Secretary and Compliance Officer Nishant Kankaria signed the official communication.

Post-Meeting Procedures

Following the board meeting conclusion, Samrat Pharmachem Limited will communicate the audited financial results to stock exchanges. The company has committed to making necessary announcements in the press and on its website as mandated under listing agreement requirements.

The pharmaceutical chemicals manufacturer operates from its registered office and factory located at GIDC Phase 4, Ankleswar, Gujarat, while maintaining its corporate office in Mumbai for administrative functions.